The University of Queensland

Evaluation of Tolebrutinib as a novel disease-modifying therapeutic for Parkinson's disease (2022–2024)

Grant type:

The Michael J Fox Foundation Therapeutic Pipeline Program

Researchers:

• 

  Dr Richard Gordon

  Honorary Associate Professor
  

  UQ Centre for Clinical Research

  Faculty of Medicine

• 

  Associate Professor John O'Sullivan

  Principal Research Fellow
  

  UQ Centre for Clinical Research

  Faculty of Medicine

• 

  Dr Rob Adam

  Trials Medical Specialist
  

  UQ Centre for Clinical Research

  Faculty of Medicine

Funded by:

The Michael J Fox Foundation for Parkinsons Research